Yes, you can have Alzheimer’s disease without dementia. In fact, Alzheimer’s pathology builds up in the brain for years, sometimes decades, before any noticeable memory problems appear. This “preclinical” phase is increasingly recognized as a distinct stage of the disease, and a surprisingly large number of older adults are walking around with Alzheimer’s-related brain changes while thinking and functioning normally.
Alzheimer’s and Dementia Are Not the Same Thing
Dementia is not a disease. It’s an umbrella term for a collection of symptoms: memory loss, confusion, difficulty reasoning, and problems with daily tasks severe enough to interfere with independent living. Many conditions can cause dementia, including vascular disease, Lewy body disease, and frontotemporal degeneration.
Alzheimer’s disease is one specific brain disease. It involves the abnormal buildup of two proteins, amyloid plaques and tau tangles, that gradually damage and destroy brain cells. Alzheimer’s is the most common cause of dementia, but the disease itself is defined by what’s happening biologically in the brain, not by whether symptoms have appeared yet. This distinction matters because it means the disease can be present long before it causes the cognitive decline we call dementia.
The Long Silent Phase
Amyloid buildup in the brain is believed to be the first sign of Alzheimer’s disease, and it can begin up to 20 years before a clinical diagnosis of dementia. For someone whose brain changes start around age 60, researchers estimate the preclinical stage (no symptoms at all) lasts roughly 13 years. For those starting at age 70, it’s about 10 years. During this entire period, the disease is biologically active but cognitively invisible.
After the silent preclinical phase, most people enter a “prodromal” stage with mild but measurable cognitive changes. This prodromal period lasts an estimated 4 years for a 70-year-old before progressing to full dementia. The total pre-dementia window, combining preclinical and prodromal stages, is roughly 17 years for someone in their early 70s. That’s a remarkably long stretch of living with Alzheimer’s pathology while still functioning independently.
How Common Is This?
More common than most people realize. A large meta-analysis published in JAMA found that among cognitively normal adults, about 10% test positive for amyloid buildup at age 50. By age 70, that figure rises to 23%. By age 90, it reaches 44%. These are people with no cognitive complaints, living their normal lives, whose brains nonetheless show the hallmark protein deposits of Alzheimer’s disease.
Genetics plays a significant role. Carrying the APOE-ε4 gene variant, the strongest known genetic risk factor for late-onset Alzheimer’s, dramatically increases the likelihood of having amyloid in the brain. Among carriers with normal cognition, nearly 48% test positive for amyloid at age 70, compared to about 17% of non-carriers. By age 90, over 80% of cognitively normal APOE-ε4 carriers have amyloid pathology. Not all of these people will develop dementia in their lifetime, but the disease process is underway.
Mild Cognitive Impairment: The Middle Ground
Between the fully silent preclinical stage and dementia, there’s a middle category called mild cognitive impairment, or MCI. People with MCI notice changes in their memory or thinking, and these changes are detectable on cognitive tests, but they can still handle daily activities independently. They pay their bills, drive, cook, and manage their medications without significant difficulty.
That independence is the key dividing line. Dementia is diagnosed when cognitive problems become severe enough to disrupt a person’s ability to function on their own. Someone with MCI due to Alzheimer’s has the disease and has symptoms, but does not have dementia. Some people with MCI remain stable for years. Others progress to dementia. And some actually improve over time.
How Preclinical Alzheimer’s Is Detected
Since there are no symptoms to report during the preclinical phase, the only way to identify Alzheimer’s pathology this early is through biomarker testing. Traditionally, this required either a spinal fluid sample to measure amyloid and tau protein levels or a specialized PET brain scan that lights up amyloid deposits.
Blood tests are now catching up. A test called PrecivityAD2 measures the ratio of two types of amyloid beta along with a specific form of tau protein (p-tau217) in the blood. In clinical studies, this blood test performed comparably to spinal fluid tests and PET scans for identifying Alzheimer’s pathology. As blood-based testing becomes more widely available, detecting Alzheimer’s before symptoms appear will become far more practical, though what to do with that information for someone who feels fine remains a complex question.
Why Some Brains Resist Symptoms Longer
Not everyone with the same amount of amyloid buildup declines at the same rate. The concept of “cognitive reserve” helps explain why. Some people’s brains appear better equipped to compensate for accumulating damage, maintaining normal function despite significant pathology underneath. Years of education, mentally stimulating activities, adequate sleep, and strong literacy skills are all associated with greater cognitive reserve. These factors don’t prevent the disease from progressing biologically, but they seem to extend the window during which the brain can work around the damage.
This is why two people with identical levels of amyloid on a PET scan can look completely different in daily life. One might already be struggling with memory, while the other runs a business and does crossword puzzles without a hitch. The disease is the same. The brain’s capacity to cope with it is not.
What This Means in Practice
Understanding that Alzheimer’s exists without dementia reshapes how the disease is thought about. It’s not a sudden event. It’s a slow biological process with a long runway, and dementia is the late stage rather than the whole story. For the roughly one in four cognitively normal 70-year-olds walking around with amyloid in their brains, the disease is present but not yet defining their lives.
This long preclinical window is also why researchers are increasingly focused on early intervention. Treatments that target amyloid or tau may have the greatest potential benefit when started before significant brain damage accumulates, during that decade-plus silent phase when the disease is detectable but symptoms haven’t emerged. Whether and when to screen cognitively healthy people remains debated, but the biology is clear: Alzheimer’s disease and dementia are not synonymous, and one can exist for a very long time without the other.